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The results show nivolumab to be a highly effective and cost-
effective end-of-life treatment option for patients with advanced, 
previously-treated RCC in Scotland. In May 2017, the SMC 
recommended nivolumab for use in routine clinical practice, with a 
patient access scheme discount agreed. Therefore, nivolumab is 
now recommended for the treatment of patients with advanced, 
previously-treated RCC across the UK. As the first licensed PD-1 
checkpoint inhibitor in RCC, nivolumab represents a notable 
advancement in current treatment options and is considered a step 




This study aimed to assess the cost effectiveness of nivolumab
versus everolimus or axitinib as monotherapies for the treatment of 
advanced, previously-treated RCC from a Scottish National Health 
Service (NHS) perspective.
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Study
Time (years)
2 3 4 5
CA209-003 (Phase I) 48%3 44%3 38%4 34%4
CA209-010 (Phase II) 42%–53%*5 33%–40%*5 29%4 NA
CheckMate 025 (Phase III) 52%2 NA NA NA
Key: NA, not available; OS, overall survival; RCC, renal cell carcinoma
Note: *Dependent on dose
Objectives
Table 1. OS rates in advanced, previously-treated RCC 
with nivolumab monotherapy 
In previously-treated patients with advanced renal cell carcinoma 
(RCC), nivolumab (OPDIVO®, a programmed death-1 [PD-1] 
checkpoint inhibitor) was the first treatment to demonstrate a 
significant overall survival (OS) benefit in the Phase III randomised 
controlled trial (RCT) CheckMate 025.
In CheckMate 025 (data cut-off June 2015, minimum follow-up 14 
months), nivolumab demonstrated a superior OS benefit compared 
with everolimus (HR: 0.73 [98.5% CI: 0.57, 0.93]).1 Plimack et al. 
later reported 2-year OS rates of 52% with nivolumab and 42% with 
everolimus.2 A summary of the OS rates observed in clinical trials 
for nivolumab in previously-treated patients with advanced RCC is 
presented in Table 1.
The improved OS observed for nivolumab-treated patients in 
CheckMate 025 is expected to translate into long-term OS benefits 
for a substantial proportion of patients. There is evidence 
supportive of an OS plateau in longer-term Phase I and II studies of 
nivolumab in previously-treated patients with advanced RCC,3, 4 and 
across other tumour types.6, 7
This combination evidence has led clinicians in the UK to expect 
that some patients with advanced, previously-treated RCC will 
achieve long-term OS benefits comparable to the general 
population if treated with nivolumab.8
A previously-reviewed de novo state-transition model was adapted 
to the NHS Scotland perspective.9 The model is based on the key 
clinical outcomes of disease progression and death. It is informed 
by CheckMate 025 data and published literature, with modelling 
assumptions clinically and economically validated for the NHS 
Scotland setting. The base case assumes efficacy and utility 
equivalence between everolimus (mTORi class) and axitinib 
(VEGFR-TKI class).
To extrapolate progression-free survival (PFS), a restricted cubic 
spline model using the odds functional form with 2 internal knots 
was fitted to reflect the change in hazards observed in CheckMate 
025 PFS data. To extrapolate OS, a range of parametric survival 
models were fitted using the six parametric model forms 
recommended for consideration in the NICE DSU TSD 14 
(exponential, Weibull, Gompertz, log-logistic, log-normal and 
generalised gamma).10 Of these parametric models, the 
generalised gamma curves were found to provide the best relative 
statistical fit to the observed data via Akaike and Bayesian 
information criteria. For long-term survival, the expected 
immunomodulatory effect of nivolumab on OS was characterised by 
assuming 50% of patients in the nivolumab arm who survived to 5 
years would have the same mortality rate as the age-matched 
general population as captured by ONS Life Tables for Scotland 
from this point onwards.11 
To incorporate patient health-related quality of life (HRQL), EQ-5D 
data were taken from CheckMate 025. The UK EQ-5D tariff was 
used to value patient questionnaire responses. A mixed model 
equation was fitted to the CheckMate 025 EQ-5D data, including 
fixed covariates for progression status and treatment arm; a 
variable interacting treatment arm with progression status; and a 
random effect for subject. 
Utility estimates used in the base-case model are 0.80 and 0.76 for 
progression-free patients, and 0.73 and 0.70 for progressed 
patients, for nivolumab and everolimus, respectively. The base-case 
model assumes utility equivalence between everolimus and axitinib.
Nivolumab is associated with an increased utility for both health 
states, which may be due to higher response rates, its 
immunotherapeutic mechanism of action and tolerable safety 
profile.
Costs used within the model reflect those incurred by NHS Scotland 
and social work services, and were taken from reference sources 
specific to the Scottish setting such as the Monthly Index of Medical 
Specialities (MIMS) and NHS reference costs.12,13 Costs are 
described as comprising four components: treatment acquisition 
and administration, disease management, adverse event resolution 
and miscellaneous (which include the costs of subsequent 
treatment and end-of-life care).
Table 2 presents the base-case results and pairwise analyses of 
incremental results, using treatment list prices as of December 
2016. Nivolumab is shown to be a highly effective therapy versus 
axitinib and everolimus, with a predicted survival benefit of 2.09 life 
years (1.15 quality-adjusted life years [QALYs]).9 
Total Incremental (nivo vs)
ICER
Costs QALYs LYs Costs QALYs LYs
Nivo £92,475 2.84 4.64
Axit £50,300 1.69 2.55 £42,175 1.15 2.09 £36,685
Ever £39,429 1.69 2.55 £53,045 1.15 2.09 £46,140
Key: axit, axitinib; ever, everolimus; ICER, incremental cost-effectiveness ratio; LY, life 
year; nivo, nivolumab; QALY, quality-adjusted life year
Table 2. Base-case results, pairwise analysis, 
nivolumab versus comparator, using list prices
To test the sensitivity of base-case results of the primary 
comparison between nivolumab and axitinib to parameter 
uncertainty, comprehensive one-way and probabilistic sensitivity 
analyses (OWSA and PSA, respectively) were run.
While the OWSA results (Figure 1) show the base-case findings to 
be most sensitive to parameter uncertainty around OS and time-to-
discontinuation model parameters, the ICER for nivolumab versus 
axitinib remained below £50,000 across all parameters tested, 
further illustrating the cost-effectiveness of nivolumab as a novel, 
end-of-life treatment option. 
PSA results indicate an 89% probability that nivolumab is a cost-
effective alternative to axitinib at a willingness-to-pay threshold of 
£50,000 per QALY gained (Figure 2).
Figure 2. PSA scatterplot, nivolumab versus axitinib, 
list prices
Figure 1. OWSA tornado diagram of 10 most influential 
parameters, nivolumab versus axitinib, list prices
Key: dep, dependent; ever, everolimus; ICER, incremental cost-effectiveness ratio; 
ind, independent; nivo, nivolumab; OS, overall survival; OWSA, one-way sensitivity 
analysis; PFS, progression-free survival; TTD, time to discontinuation
Key: ICER, incremental cost-effectiveness ratio; PSA, probabilistic sensitivity analysis; 
QALY, quality-adjusted life year; WTP, willingness-to-pay
